HHS to dole out $15B to Medicaid, CHIP providers and $10B to safety-net hospitals AstraZeneca aims to get COVID-19 therapy into clinic in 2 months BIO: Is COVID-19 changing how biopharmas think of M&A? Not really, say J&J and Takeda execs BIO: Boehringer BD head Sapountzis on striking deals during COVID-19 Biopharma roundup: GSK tests antibodies against cytokine storm; WHO expert walks back statement on virus' spread Healthcare roundup: BCBSRI offers 25% dental premium credit Amwell CEOs on the telehealth boom and why it will 'democratize' healthcare Anthem reaffirms 2020 earnings guidance amid COVID-19 uncertainty Featured Story | Tuesday, June 9, 2020 HHS plans to distribute $25 billion this week to providers reliant on Medicaid and CHIP after criticism on how the initial rounds of a $175 billion relief fund were distributed. read more |
| |
|---|
|
Top Stories Tuesday, June 9, 2020 AstraZeneca is planning to start a phase 1 clinical trial of a COVID-19 antibody therapy within two months. The commitment follows the signing of a deal that grants AstraZeneca an exclusive license to six anti-SARS-CoV-2 antibodies identified by researchers at Vanderbilt University. read more Tuesday, June 9, 2020 Biopharma M&A has seen a sharp decline so far this year, both in terms of monetary value and total transaction count, amid a COVID-19 business slowdown. But executives from Johnson & Johnson, Takeda and Horizon Therapeutics said their companies' M&A strategies remain unchanged. read more Tuesday, June 9, 2020 The COVID-19 pandemic has thrown a curve ball at the global economy, and the biopharma industry is no exception. Companies are scrambling to develop tests, treatments and vaccines for the disease, while making sure not to neglect their pipelines. We caught up with Ioannis Sapountzis, Boehringer Ingelheim’s global head of business development and licensing, to see how the German pharma is handling this. read more Tuesday, June 9, 2020 AstraZeneca has "lost interest" in a potentially record-setting merger with Gilead, The Times of London reported. GlaxoSmithKline will test its arthritis antibody otilimab in severely-ill COVID patients. Plus, Fujifilm plans to invest nearly $1 billion in a former Biogen plant, and a WHO expert walked back claims about how the virus spreads. read more Tuesday, June 9, 2020 Follow along with the latest COVID-19 news straight from the FierceHealthcare team. read more Tuesday, June 9, 2020 Amid reports that the company plans to go public, Amwell CEOs Roy and Ido Schoenberg talk to FierceHealthcare about the future of telehealth. Find out why the executives believe the surge in virtual visits represents "nothing short of a revolution" in healthcare. read more Tuesday, June 9, 2020 Anthem is reaffirming its 2020 guidance and will be reaching out to investors over the next several weeks, according to financial documents. read more |
